Showing 341-350 of 3239 results for "".
- Severe Psoriasis Increases Risk for Heart Diseasehttps://practicaldermatology.com/news/severe-psoriasis-increases-risk-for-heart-disease/2462013/Researchers have found further evidence that patients with severe psoriasis are at higher risk for cardiovascular disease. In this study, a total of 503 patients with psoriasis, and without clinical cardiovascular disease, underwent transthoracic Doppler echocardiography to evaluate cor
- PFAS Exposure Linked to Melanoma in Womenhttps://practicaldermatology.com/news/pfas-exposure-linked-to-melanoma-in-women/2462011/Exposure to PFAS (per- and poly-fluoroalkyl substances) and phenols may be linked to diagnoses of melanoma and other cancers, new research suggests. Women who reported higher levels of exposure to PFDE, a long-chained PFAS compound, had double the odds of a previous melanoma diagnosis;
- Encouraging Preclinical Results Seen for Scinai’s NanoAbs in Plaque Psoriasishttps://practicaldermatology.com/news/encouraging-preclinical-results-seen-for-scinais-nanoabs-in-plaque-psoriasis/2462006/Scinai Immunotherapeutics Ltd.’s anti‑interleukin 17 (IL‑17) NanoAbs downregulated key molecular markers that are overexpressed in plaque psoriasis, according to preclinical data relased by Scinai. Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-
- New App-controlled Device May Help Quickly Identify Infected Woundshttps://practicaldermatology.com/news/new-app-controlled-device-may-help-quickly-identify-infected-wounds/2461959/A new app-controlled device may allow doctors to spot infected wounds faster. The scientists developed a device called the Swift Ray 1 which can be attached to a smartphone and connected to the Swift Skin and Wound software. It can take medical-grade photographs, inf
- Inmagene's OX40 mAb Enters POC Study in ADhttps://practicaldermatology.com/news/inmagenes-ox40-mab-enters-poc-study-in-ad/2461934/The first patient has been dosed in a global multicenter proof-of-concept (POC) study of Inmagene Biopharmaceuticals’ IMG-007 in adults with moderate-to-severe atopic dermatitis (AD). The objective of the study is to assess the safety, pharmacokinetics, and efficacy of
- AD Pipeline Watch: Apogee Therapeutics, Inc.’s IL-13 Blocker Enters Phase 1 Trialhttps://practicaldermatology.com/news/ad-pipeline-watch-apogee-therapeutics-incs-il-13-blocker-enters-phase-1-trial/2461911/The first volunteers have been dosed in a Phase 1 trial for
- Revealed: Why Tans Appear After Leaving the Beachhttps://practicaldermatology.com/news/revealed-why-tans-appear-after-leaving-the-beach/2461906/New research uncovers the science behind why the body's tanning process does not occur immediately after sun exposure, but only after a few hours or even days. The mechanism that repairs our DNA takes precedence over all other systems in the cell, temporarily inhibiting the pi
- Reinforcement Learning Model May Boost AI Skin Cancer Diagnosis Accuracyhttps://practicaldermatology.com/news/reinforcement-learning-model-may-boost-ai-skin-cancer-diagnosis-accuracy/2461897/Artificial intelligence (AI) is already being used to diagnose skin cancer, but so far, it can’t keep pace with the complex decision-making of doctors in practice. Now, an international research team is developing a learning method in which greater accuracy in AI results can be a
- LRP Celebrates Acne Positivity with Two-Day 'Positivity Lab' Pop-Up Experience in NYChttps://practicaldermatology.com/news/lrp-celebrates-acne-positivity-with-two-day-positivity-lab-pop-up-experience-in-nyc/2461879/La Roche-Posay is hosting a consumer pop-up experience to help destigmatize acne. The pop-up will feature an immersive "Science of Skin" exhibit, a meditation lounge in partnership with obé Fitness, Doodle Bar with custom art done by local artists, and a Positivity Phot
- DFD-29 Bests Competition for Papulopustular Rosacea in Adultshttps://practicaldermatology.com/news/dfd-29-bests-competition-for-papulopustular-rosacea-in-adults/2461858/Minocycline Hydrochloride Modified Release Capsules (DFD-29) outperformed Oracea (doxycycline) capsules and placebo for the treatment of moderate-to-severe papulopustular rosacea in adults, according to positive topline results from two Phase 3 studies. Journey Medical&rs